Optimising the therapeutic efficacy of anti-inflammatory macrophages for use in chronic kidney diseases

慢性肾脏病（CKD）是澳大利亚死亡和发病的主要原因。目前能够延迟CKD进展的治疗方法有限。因此，每年有超过2300名澳大利亚人需要肾脏置换，更多的人死于肾衰竭。我们通过给予保护性白色血细胞-巨噬细胞减少并预防了CKD小鼠模型的损伤。该项目将对巨噬细胞进行体外修饰，以优化其用于CKD的治疗。

Chronic kidney disease (CKD) is a major cause of death and morbidity in Australia. Current treatments that are able to delay progression for CKD are limited. As a consequence, more than 2300 additional Australians need kidney replacement each year and many more die of kidney failure. We have reduced and prevented injury in a mouse model of CKD by administering protective white blood cells - macrophages. This project will modify macrophages ex vivo to optimize them for use as a therapy for CKD.